CLAIM CARD
A notable tension within the dosing and pharmacokinetics evidence base is the absence of corroborating data from other independent analyses within this curated corpus, as the Chen 2026 network meta-analysis represents the sole source of agent-specific safety quantification for intestinal obstruction. By contrast, the broader SGLT2 inhibitor literature has emphasized cardiovascular and renal benefits, with gastrointestinal safety receiving comparatively less systematic attention. The specific finding for canagliflozin raises questions about whether this signal persists across different study populations, durations of exposure, and comparator definitions. Establishing the boundary conditions for this pharmacokinetic safety signal — including whether it is dose-dependent or attenuated with longer follow-up — remains an important unresolved question for the field.
Evidence grade: exploratory
Contradiction status: none
Publication: f0b4aa8b-f260-4fc6-8419-dac0b0a34715
Provenance: Derivation Web chain
Citation Support
source_1Movila 2026source_2Borges 2024source_3Jansz 2026source_4Ali 2026source_5Cersosimo 2025